What Is Fatty Liver Disease (NAFLD)?

Fatty liver disease has emerged as one of the most consequential chronic conditions of the modern era. The condition, also called non-alcoholic fatty liver disease (NAFLD) and increasingly called metabolic dysfunction-associated steatotic liver disease (MASLD) under newer terminology, affects approximately 25 to 30 percent of the global adult population. The numbers reflect a substantial global epidemic that has paralleled the rise in obesity, type 2 diabetes, and related metabolic conditions over recent decades. Yet despite this enormous prevalence, the condition remains poorly recognized by patients and sometimes underdiagnosed by clinicians, with many cases identified only incidentally through abnormal liver tests or imaging performed for other reasons.

The condition derives its name from the accumulation of fat within liver cells. Under normal circumstances, the liver contains minimal fat. In fatty liver disease, the proportion of liver tissue consisting of fat exceeds 5 percent, with the excess accumulation reflecting various metabolic disturbances. The fat itself is initially relatively benign, with many patients having no symptoms and no progressive disease. Yet for a substantial subset of patients, the simple fat accumulation progresses to inflammation (called non-alcoholic steatohepatitis or NASH), then to scarring (fibrosis), and ultimately to cirrhosis with all its serious complications. Understanding which patients will progress and which will remain stable is among the central challenges in fatty liver disease.

The connection to broader metabolic health is fundamental. Fatty liver disease rarely occurs in isolation. The condition is closely linked to insulin resistance, type 2 diabetes, obesity, dyslipidemia, hypertension, and cardiovascular disease. The constellation of these conditions reflects what is called metabolic syndrome, with fatty liver disease often described as the hepatic manifestation of metabolic syndrome. The shared underlying mechanisms mean that fatty liver disease both reflects and contributes to overall metabolic dysfunction.

The clinical importance of fatty liver disease has grown substantially as understanding has advanced. The condition is now recognized as a leading cause of cirrhosis worldwide and a substantial contributor to liver-related mortality. The cardiovascular implications mean that patients with fatty liver disease face elevated risks of heart attacks and strokes that may exceed their liver-related risks. The combination of liver and cardiovascular consequences makes the condition substantially more important than its often-asymptomatic nature might suggest.

This article serves as a comprehensive introduction to fatty liver disease. It explains what the condition actually is and how it develops, identifies who is affected and what risk factors contribute, examines the symptoms and how the condition is diagnosed, discusses the spectrum of disease from simple fat accumulation through cirrhosis, and frames treatment approaches. The understanding supports both informed self-awareness and productive engagement with healthcare.

⸻

What Fatty Liver Disease Actually Is

Understanding what happens in fatty liver disease provides the foundation for understanding everything else about the condition.

Normal Liver Function

The liver is among the most metabolically active organs in the body. It processes nutrients absorbed from the digestive tract, produces various essential proteins, breaks down medications and toxins, stores energy in the form of glycogen, produces bile for fat digestion, and various other functions. Under normal circumstances, liver tissue contains minimal fat. The liver actively processes fats but does not accumulate them in the cells themselves.

Fat Accumulation

In fatty liver disease, fat accumulates within the liver cells (hepatocytes). The accumulation reflects an imbalance between fat delivery to the liver, fat production within the liver, and fat export from the liver. When the proportion of fat exceeds 5 percent of liver tissue, the condition is called fatty liver or steatosis. This is the defining feature. The fat that accumulates is primarily triglycerides, which form droplets within the liver cells. The droplets can be observed microscopically and detected through various imaging techniques.

Why Fat Accumulates

Various mechanisms contribute to fat accumulation in the liver.

• Increased fat delivery from the diet or from fat tissue throughout the body provides more substrate.
• Increased fat production within the liver itself, called de novo lipogenesis, contributes substantially. The process is stimulated by various factors including high carbohydrate intake, particularly fructose, and insulin resistance.
• Decreased fat export from the liver in the form of very low density lipoproteins (VLDL) reduces fat removal.
• Decreased fat oxidation (burning) within the liver also contributes.

The combination of these mechanisms varies among patients. Insulin resistance is a central contributor in most cases.

From NAFLD to MASLD

The terminology for fatty liver disease has evolved. Non-alcoholic fatty liver disease (NAFLD) was the historic term, defined by exclusion of alcohol as a cause. In 2023, international expert groups proposed updated terminology. Metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes the metabolic basis of the condition rather than defining it by absence of alcohol. The newer terminology is being adopted progressively but the older NAFLD terminology remains widely used. Both terms refer to essentially the same condition. This article uses NAFLD for clarity, with the understanding that MASLD terminology is increasingly used.

⸻

Who Gets Fatty Liver Disease

Fatty liver disease is among the most common medical conditions globally.

Prevalence

NAFLD affects approximately 25 to 30 percent of adults globally. Some populations have substantially higher rates. The prevalence has increased substantially over recent decades, paralleling rises in obesity and type 2 diabetes. The increase has occurred in adults and increasingly in children and adolescents.

Risk Factors

Various factors increase risk of fatty liver disease.

• Obesity is the strongest risk factor. The risk increases progressively with increasing body weight. Visceral obesity (abdominal fat) particularly increases risk.
• Type 2 diabetes affects most patients with NAFLD, and most patients with type 2 diabetes have NAFLD. The bidirectional relationship reflects shared underlying mechanisms.
• Insulin resistance, even without diabetes, increases NAFLD risk substantially.
• Dyslipidemia, particularly elevated triglycerides and low HDL cholesterol, is associated with NAFLD.
• Hypertension is associated with NAFLD.
• Metabolic syndrome (the combination of various risk factors) is closely associated with NAFLD.
• Genetic factors affect susceptibility. Specific variants in genes including PNPLA3, TM6SF2, and various others affect both risk and progression.
• Diet patterns affect risk. High intake of refined carbohydrates, sugar (particularly fructose), and ultraprocessed foods is associated with increased risk.
• Sedentary lifestyle increases risk.
• Various medications can contribute to fatty liver including corticosteroids, methotrexate, amiodarone, and various others.
• Various other conditions including polycystic ovary syndrome, hypothyroidism, hypopituitarism, and various others can contribute.

Demographics

NAFLD affects all age groups including children. The prevalence increases with age. Men have somewhat higher prevalence than women in some populations, with patterns varying. Various ethnic groups have different patterns of prevalence and progression risk.

⸻

Symptoms

Most patients with NAFLD have no symptoms attributable to the condition itself.

Asymptomatic Disease

The asymptomatic nature of NAFLD is among its most challenging characteristics. Most patients are unaware they have the condition. The lack of symptoms means that diagnosis often occurs incidentally through abnormal liver tests or imaging performed for other reasons. Some patients are diagnosed when they undergo evaluation for other conditions.

Possible Symptoms

When symptoms occur in NAFLD, they tend to be nonspecific.

• Fatigue is sometimes reported. The fatigue may reflect the metabolic derangements rather than direct liver dysfunction.
• Right upper abdominal discomfort or fullness can occur, possibly reflecting liver enlargement.
• Various other vague symptoms can occur but are not specific.

Symptoms of Advanced Disease

In patients who progress to cirrhosis, symptoms of advanced liver disease can develop. These include jaundice (yellowing of skin and eyes), ascites (fluid accumulation in the abdomen), bleeding from varices, hepatic encephalopathy (mental status changes from liver dysfunction), and various others. The development of these symptoms typically indicates substantial liver damage that has progressed over years.

Why Symptoms Often Lag

The lack of symptoms reflects the substantial reserve capacity of the liver. The organ can function with substantial damage before producing symptoms. By the time symptoms develop, substantial damage has often accumulated. This characteristic emphasizes the importance of identifying NAFLD before symptoms develop, when intervention has greater potential benefit.

⸻

How NAFLD Is Diagnosed

Diagnosis of NAFLD involves several elements.

Clinical Evaluation

Clinical evaluation considers risk factors. Patients with obesity, type 2 diabetes, metabolic syndrome, and various other features have elevated NAFLD probability.

Liver Function Tests

Blood tests evaluating liver function are commonly the first indicator of NAFLD.

• ALT (alanine aminotransferase) is often modestly elevated in NAFLD. Normal levels do not exclude NAFLD; many patients have NAFLD with normal liver tests.
• AST (aspartate aminotransferase) may also be elevated.
• The pattern with ALT typically higher than AST is suggestive of NAFLD, distinguishing it from alcohol-related liver disease where AST is often higher than ALT.
• GGT (gamma-glutamyl transferase) and alkaline phosphatase may also be elevated.

Imaging

Various imaging techniques can identify hepatic steatosis (fatty liver).

• Ultrasound is widely used and can detect significant steatosis. The technique is particularly useful for routine evaluation.
• CT scanning can detect steatosis but uses radiation.
• MRI is the most sensitive and accurate technique. MRI proton density fat fraction (MRI-PDFF) provides quantitative assessment.

Specialized Studies

Various specialized studies evaluate the spectrum of disease.

• FibroScan (transient elastography) measures liver stiffness, which correlates with fibrosis. The technique provides important information about disease severity without requiring biopsy.
• MR elastography is another technique evaluating liver stiffness.
• Various blood test panels combine multiple parameters to estimate fibrosis risk. The FIB-4 score, NAFLD fibrosis score, and various others guide assessment.

Liver Biopsy

Liver biopsy remains the gold standard for definitive diagnosis and assessment of disease severity. The technique provides direct examination of liver tissue. Biopsy is reserved for situations where the information will affect management. Most patients can be evaluated and managed without biopsy.

Excluding Other Conditions

Various other conditions can cause similar findings. Hepatitis B, hepatitis C, autoimmune hepatitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, and various others may need exclusion in specific situations. Alcohol consumption history affects classification. Significant alcohol intake (more than 21 drinks per week for men or 14 for women) suggests alcohol-related liver disease rather than NAFLD.

For more on related considerations, see NAFLD vs NASH: What's the Difference?.

⸻

The Spectrum of Disease

NAFLD encompasses a spectrum from simple fat accumulation to cirrhosis.

Simple Steatosis (NAFL)

Simple steatosis or non-alcoholic fatty liver (NAFL) involves fat accumulation without significant inflammation or scarring. Most NAFLD patients have this form. Simple steatosis carries relatively low risk of progression to cirrhosis. The condition is associated with cardiovascular risk through shared metabolic mechanisms but has limited liver-specific consequences in most patients.

Steatohepatitis (NASH)

Non-alcoholic steatohepatitis (NASH) involves fat accumulation with inflammation and liver cell injury. Approximately 20 to 30 percent of NAFLD patients have NASH. NASH carries higher risk of progression to fibrosis and ultimately cirrhosis. Identification of NASH affects management and monitoring.

Fibrosis

Fibrosis involves scarring of liver tissue from chronic injury. Various stages of fibrosis exist, from mild (stage 1) to advanced (stage 3) and ultimately cirrhosis (stage 4). The degree of fibrosis is the strongest predictor of liver-related complications and mortality.

Cirrhosis

Cirrhosis represents end-stage liver scarring. The condition involves substantial structural changes and impaired liver function. Patients with cirrhosis from NAFLD face risks of liver decompensation, hepatocellular carcinoma, and various other complications.

For more detailed coverage of disease stages, see Stages of Fatty Liver Disease.

Progression and Regression

The course of NAFLD varies among patients. Some patients have stable disease over decades. Others progress through the disease spectrum. Progression is generally slow, occurring over years to decades. Various factors including age, diabetes, severity of obesity, and various others affect progression risk. Importantly, NAFLD can regress with appropriate intervention. Weight loss, control of underlying conditions, and various other interventions can reduce fat accumulation and even improve fibrosis in some patients.

For more on reversibility, see Can Fatty Liver Be Reversed?.

⸻

Why NAFLD Matters

The clinical importance of NAFLD reflects multiple aspects.

Liver Consequences

NAFLD is now a leading cause of cirrhosis worldwide. As hepatitis C treatment has improved and chronic alcohol-related cirrhosis has declined relatively, NAFLD-related cirrhosis has emerged as the leading cause in many populations. NAFLD is also a leading reason for liver transplantation. Hepatocellular carcinoma can develop in NAFLD patients with cirrhosis and even occasionally without cirrhosis.

Cardiovascular Consequences

Cardiovascular disease is the leading cause of death in NAFLD patients, often exceeding liver-related mortality. Patients with NAFLD have elevated risks of heart attack, stroke, and various other cardiovascular events. The risks reflect both the shared metabolic mechanisms and possibly direct contributions from the liver disease itself.

For more on cardiovascular connections, see related articles in the metabolic health section.

Other Health Consequences

NAFLD is associated with increased risk of various cancers, chronic kidney disease, sleep apnea, and various other conditions. The breadth of associations reflects the metabolic dysfunction underlying NAFLD.

Quality of Life

Quality of life can be affected by NAFLD even in asymptomatic patients. The diagnosis itself affects some patients. Fatigue and various other vague symptoms affect others.

⸻

Treatment

Treatment of NAFLD focuses on addressing underlying metabolic dysfunction and modifying disease progression.

Lifestyle Modifications

Lifestyle modifications form the foundation of NAFLD treatment.

• Weight loss is the most effective intervention for most patients. Loss of 5 to 10 percent of body weight produces substantial improvements in liver fat, liver inflammation, and fibrosis.
• Dietary modifications include reducing total caloric intake, reducing simple carbohydrates and added sugars, reducing saturated fat, and increasing fiber intake. The Mediterranean dietary pattern has demonstrated specific benefits for NAFLD.
• Physical activity benefits NAFLD independently of weight loss. Both aerobic exercise and resistance exercise contribute. The recommendations include at least 150 minutes per week of moderate aerobic activity.

For more on exercise, see Best Exercise for Fatty Liver Disease.

Treatment of Associated Conditions

Treatment of associated conditions addresses both those conditions and NAFLD.

• Diabetes management with various medications including metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and various others can affect NAFLD outcomes.
• Cardiovascular risk factor management including blood pressure and cholesterol affects overall outcomes.

Specific NAFLD Medications

Until recently, no medications were specifically approved for NAFLD. The treatment landscape has evolved.

• Resmetirom, a thyroid hormone receptor beta agonist, became the first FDA-approved medication specifically for NASH with significant fibrosis in 2024. The medication targets specific liver pathways and has shown improvements in fibrosis.
• Various other medications are in development.
• GLP-1 receptor agonists including semaglutide have shown benefits in NAFLD beyond their direct effects on weight and diabetes.
• Vitamin E has been studied in NASH with some demonstrated benefit.
• Pioglitazone has been studied in NASH with some demonstrated benefit, though side effects affect use.

Bariatric Surgery

For patients with severe obesity, bariatric surgery produces substantial weight loss and corresponding improvements in NAFLD. The procedures can produce dramatic improvements including in fibrosis.

Liver Transplantation

For patients with end-stage liver disease from NAFLD, liver transplantation is appropriate. NAFLD-related cirrhosis has become an increasingly common indication for liver transplantation.

⸻

Monitoring and Follow-Up

Monitoring of NAFLD patients involves several elements.

Periodic Evaluation

Periodic evaluation typically includes liver function tests, assessment of metabolic risk factors, and imaging or non-invasive fibrosis assessment.

Risk Stratification

Risk stratification identifies patients at higher risk of progression. The FIB-4 score and various other tools support stratification.

Specialist Referral

Specialist referral is appropriate for patients with significant fibrosis, those who may benefit from specific therapies, and those with various other indications.

Cardiovascular Risk Assessment

Cardiovascular risk assessment is important given the substantial cardiovascular consequences of NAFLD.

Surveillance for Complications

For patients with cirrhosis, surveillance for hepatocellular carcinoma is appropriate.

⸻

Special Patient Populations

Several specific populations have particular considerations.

Patients With Diabetes

Most patients with type 2 diabetes have NAFLD. Coordinated management addresses both conditions.

Pediatric Patients

NAFLD increasingly affects children and adolescents. Pediatric NAFLD has specific considerations.

Lean Patients

Some NAFLD patients have normal body weight (lean NAFLD). The condition has somewhat different characteristics and may warrant specific evaluation.

Patients With Other Liver Conditions

Patients with other liver conditions can also have NAFLD. The combination affects management.

For more on alcohol-related distinction, see Alcohol vs Non-Alcoholic Fatty Liver Disease.

⸻

Common Misconceptions

Several misconceptions about NAFLD deserve attention.

Misconception: NAFLD Is Caused by Alcohol

NAFLD is by definition not caused by alcohol. Alcohol-related liver disease is a separate condition.

Misconception: NAFLD Is Always Mild

While most NAFLD is non-progressive, a substantial subset progresses to serious complications. The diagnosis warrants attention.

Misconception: Normal Liver Tests Exclude NAFLD

Many patients have NAFLD with normal liver tests. Imaging or other evaluation may be needed.

Misconception: Only Overweight People Get NAFLD

While obesity is the strongest risk factor, lean people can develop NAFLD.

Misconception: NAFLD Has No Treatment

Lifestyle modifications, control of associated conditions, and increasingly specific medications all affect NAFLD.

Misconception: NAFLD Cannot Be Reversed

NAFLD can substantially improve with appropriate intervention.

For more on misdiagnosis broadly, see Most Commonly Misdiagnosed Conditions.

⸻

When to See a Specialist

Several types of specialists may be involved in NAFLD care. Primary care providers manage many NAFLD patients. Hepatologists (liver specialists) and gastroenterologists evaluate patients with significant disease. Endocrinologists may be involved for patients with diabetes or other metabolic conditions. Cardiologists may be involved for cardiovascular risk management. Various other specialists contribute as needed.

⸻

Conclusion

Non-alcoholic fatty liver disease (NAFLD), now increasingly called metabolic dysfunction-associated steatotic liver disease (MASLD), affects approximately 25 to 30 percent of adults globally. The condition involves accumulation of fat in liver cells with various potential consequences ranging from minimal to severe.

Risk factors include obesity, type 2 diabetes, insulin resistance, dyslipidemia, hypertension, metabolic syndrome, genetic factors, dietary patterns, and sedentary lifestyle. The condition shares underlying mechanisms with various other metabolic conditions.

Most patients have no symptoms. Diagnosis often occurs incidentally through abnormal liver tests or imaging. Various testing approaches including liver function tests, imaging including ultrasound and MRI, specialized studies including transient elastography, and occasionally liver biopsy support diagnosis and assessment.

The disease spectrum includes simple steatosis (most common, lower risk), steatohepatitis (NASH, higher risk), fibrosis (variable severity), and cirrhosis. Progression occurs in a subset of patients over years to decades.

The clinical importance reflects multiple aspects. NAFLD is now a leading cause of cirrhosis and liver transplantation. Cardiovascular consequences often exceed liver-related risks. Various other health conditions are associated.

Treatment focuses on lifestyle modifications including weight loss, dietary changes, and physical activity, along with treatment of associated conditions. Specific medications including resmetirom (newly approved), GLP-1 receptor agonists, and various others continue to evolve. Bariatric surgery and liver transplantation address selected situations.

The encouraging element of NAFLD is that the condition can substantially improve with appropriate intervention. Weight loss of 5 to 10 percent produces substantial improvements. The combination of lifestyle modifications with targeted medications when appropriate produces good outcomes for most patients.

For most patients with NAFLD or at risk for the condition, the practical messages are clear. Recognize that the asymptomatic nature does not mean unimportant. Engage with lifestyle modifications that address both NAFLD and related metabolic conditions. Monitor for progression in higher-risk patients. Consider specialist evaluation when appropriate. The combination of patient engagement, comprehensive care, and continued advances in understanding and treatment provides the foundation for the best possible outcomes for this common but consequential condition.

⸻

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.